Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG09222 for the Prevention of Migraine in Participants With Unsuccessful Prior Preventive Treatments
NCT06323928Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Modality
- IgG Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of lu ag09222 in migraine, sponsored by Lundbeck. Started Apr 2024; status: completed.
02
Drugs
lu ag09222
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06323928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323928.